At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 812 enrolled
Drug / intervention
Nivolumabdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An Open-Label, Multicenter Clinical Trial With Nivolumab (BMS-936558) Monotherapy in Subjects With Advanced or Metastatic Squamous Cell (Sq) Non-Small Cell Lung Cancer (NSCLC) Who Have Received at Least One Prior Systemic Regimen for the Treatment of Stage IIIb/IV SqNSCLC
In Brief
A Phase 2 clinical trial evaluating Nivolumab for Non-Small Cell Lung Cancer. Completed, enrolled 812 participants across 90 sites in 13 countries.
Detailed Summary
The purpose of the study is to determine the occurrence of high-grade (CTCAE v4.0 Grades 3-4), treatment-related, select adverse events in patients with advanced or metastatic Squamous Cell Non-Small Cell Lung Cancer (SqNSCLC) with progression of disease during or after at least 1 systemic therapy.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsNon-Small Cell Lung Cancer
CountriesAustria, Denmark, Finland, Greece, Hungary, Ireland, Poland, Portugal, Romania, Russia, Spain, Sweden, United Kingdom
CollaboratorsPPD Development, LP
Timeline
Phase 2CompletedFinished
201520162017201820192020202120222023202420252026
First PostedApr 2015
Enrollment StartApr 2015
Primary CompletionMar 2018
Study CompletionAug 2021
TodayJul 2026
First PostedApr 6, 2015
Enrollment StartApr 29, 2015
Primary CompletionMar 7, 2018
Study CompletionAug 27, 2021
TodayJul 2, 2026
Enrollment to primary: 2.9 yearsPosted 11.2 years ago
Interventions
Nivolumabdrug